AnaptysBio’s PD-1 drug reduces rheumatoid arthritis in phase 2 trial

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has hit the goals of a phase 2 rheumatoid arthritis (RA) trial.